



PRESENTER BIOS AND DISCLOSURES

Rare Cardiac Conditions Conference
Plenary Session
Friday, February 24, 2023

Presenters	Bio sketch
<p>Ian Paterson MD, FRCPC</p>	<p>Ian Paterson, MD, is a cardiologist at the University of Ottawa Heart Institute and a professor in the Faculty of Medicine at the University of Ottawa.</p> <p>Dr. Paterson received his medical degree from McGill University in 1995. He completed post-graduate medical training in internal medicine, cardiology, and echocardiography in 2002. He subsequently completed a fellowship in cardiac magnetic resonance imaging (MRI) at the National Institutes of Health. The University of Alberta recruited him to its division of cardiology in 2004. Dr. Paterson served as director of residency training in adult cardiology from 2009-2017. He continued as an associate program director thereafter. Dr. Paterson was co-founder and clinical director of the Edmonton Cardio-Oncology Program and academic/research director for cardiac MRI at the Mazankowski Alberta Heart Institute.</p> <p>Dr. Paterson is a board member of the Canadian Cardiac Oncology Network and the Canadian Society of Cardiovascular Magnetic Resonance. He has chaired and/or co-authored position statements and guidelines, and has led CIHR-funded, multi-centre clinical trials in cardio-oncology and cardiac MRI.</p> <p>Dr. Paterson joined the UOHI in 2022 as co-lead of the Cardiac MRI Program and director of the Canadian Centre for Rare Cardiac Conditions.</p> <p>Dr. Paterson's research interests include cardiovascular imaging in heart failure, cardiomyopathy, cardio-oncology, and post-COVID syndrome. He has published hundreds of scientific articles, abstracts, and book chapters, and frequently presents his research regionally, nationally, and internationally.</p>
<p>Andrew D. Krahn, MD, FCCS, FHRS</p>	<p>Dr. Krahn is a Professor in the Division of Cardiology at the University of British Columbia. He received his MD from the University of Manitoba. His clinical expertise is in management of cardiac arrhythmias. Current research interests include investigation of genetic causes of arrhythmias, causes of loss of consciousness and implantable arrhythmia devices.</p> <p>Dr. Krahn has research funded by a Foundation grant from the Canadian Institute of Health Research through 2027. His research has been published in numerous high impact scientific journals such as Circulation, JAMA, Journal of the American College of Cardiology, the New England Journal of Medicine, and the European Heart Journal. He founded the Hearts in Rhythm Organization (HiRO – www.heartsinrhythm.ca). He has published >400 papers in peer-reviewed journals. He sits on the Editorial Board of the Canadian Journal of Cardiology, Heart Rhythm and the Journal of Cardiovascular Electrophysiology.</p> <p>Dr. Krahn is affiliated with several professional associations including the Royal College of Physicians of Canada, the Canadian Cardiovascular Society, and the Heart Rhythm Society. He is past President of the Canadian Cardiovascular Society, and President of the Heart Rhythm Society. He is the Sauder Family Chair and Chief of Cardiology, and the Paul Brunet Chair in Heart rhythm Disorders.</p>



David Birnie
BSc (Hons),
MB, ChB,
MRCP, MD

David Birnie, MD, is a staff cardiac electrophysiologist, Vered Chair, and the division head of Cardiology at the University of Ottawa Heart Institute. He is a full professor in the Division of Cardiology, Department of Medicine, at the University of Ottawa, where he is cross-appointed to the School of Epidemiology and Public Health, Faculty of Medicine. Dr. Birnie co-leads the Ottawa Region strategic research Innovation Cluster on Arrhythmias.

Dr. David Birnie received his medical degree (MB ChB) from Glasgow University in 1990. After completion of Internal Medical training at Aberdeen University he gained his MRCP (UK) in 1993. He spent three years as a cardiology research fellow at Glasgow University from 1993 studying the immunology of atherosclerosis and was awarded his PhD equivalent (MD) in 1996. Between 1996 and 2001 he undertook cardiology training at Glasgow University and received his Certificate of Completion of Specialist Cardiology Training in 2001. In addition he spent a year in 1999-2000 as a Cardiac Electrophysiology Fellow at the University of Ottawa Heart Institute. Dr. Birnie was recruited to the University of Ottawa Heart Institute in 2002 as staff cardiac electrophysiologist and clinician investigator.

Dr. Birnie is a founding member and current chair of the Canadian Heart Rhythm Society Research Committee. He is chair of the first international guidelines for the diagnosis and management of cardiac sarcoidosis. He currently sits on both Canadian Institutes of Health Research (CIHR) and Heart and Stroke Foundation peer review panels.

Dr. Birnie, as principal investigator, has been funded by the British Heart Foundation, HSFC, CIHR and the JP Bickell Foundation. Dr. Birnie has current grant funding from HSFC and CIHR. He played a leading role as Co-Principal Investigator on the CIHR Canadian Atrial Fibrillation Stroke Prevention Network (2013-2019).

To date, he has been involved in over 500 peer-reviewed presentations, publications, and book chapters. In 2014, Dr. Birnie was awarded the University of Ottawa Heart Institute's Clinical Science Investigator of the Year award and the Global Achievement Award in 2016. In 2018 he was awarded the prestigious University of Ottawa Department of Medicine Mentorship Award. Dr. Birnie has been an invited speaker at major international conferences including the American Heart Association, Heart Rhythm Society and the Canadian Cardiovascular Society meeting. He has managed to combine work with his major hobby, serving as cardiologist for the Medical Advisory Committee of the Canadian Soccer Association.

Dr. Birnie heads the Division of Cardiology at the UOHI. His clinical focus is on all aspects of cardiac electrophysiology including arrhythmia pharmacotherapy and radiofrequency ablation of simple and complex arrhythmias including atrial fibrillation. He also co-leads the cardiac sarcoidosis clinic and program. He also has a major clinical interest in all aspects of implantation and follow-up of device therapy for arrhythmias. This includes pacemakers, implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy (CRT).

Dr. Birnie's major ongoing research interests are cardiac sarcoidosis, selection and optimization of CRT for heart failure patients, investigating optimal strategies for stroke reduction after AF ablation.



<p>Jodi Edwards PhD</p>	<p>Dr. Jodi Edwards is the Director of the Brain and Heart Nexus Research Program at the University of Ottawa Heart Institute (UOHI), Associate Professor in the School of Epidemiology and Public Health at the University of Ottawa, Director of the UOHI Population Outcomes Research Unit and an ICES Adjunct Scientist.</p> <p>Dr. Edwards' expertise is in cardiovascular epidemiology and her research focuses on risk assessment and predictive modeling for the heart-brain interface, clinical prediction tools and neuromodulation interventions for recovery.</p> <p>Dr. Edwards receives funding from CIHR, the Canadian Cardiovascular Society, the Heart and Stroke Foundation of Canada and Brain Canada and was awarded the 2020 Heart and Stroke Foundation (HSF) National New Investigator in Women's Heart and Brain Health award, UOHI Investigator of the Year, and Faculty of Medicine Early Career Researcher of the Year. Dr. Edwards publishes extensively in leading clinical journals and has received national media attention for her work.</p> <p>She is Co-PI of the Canadian Platform for Trials in Non-Invasive Brain Stimulation and Co-Chairs the International Stroke Recovery and Rehabilitation Alliance Roundtable on Non-Invasive Brain Stimulation and the Health Systems and Policy Working Group for the Canadian Women's Heart Health Alliance and is lead PI on the recently awarded CIHR Clinical Trials Training Platform for the STROKECOG Platform for innovative clinical trial training initiatives in stroke and cognition.</p>
<p>Gavin Oudit MD PhD FRCPC</p>	<p>Dr. Gavin Oudit is a Professor, Staff Cardiologist and Clinician-Scientist at the Mazankowski Alberta Heart Institute, University of Alberta. His clinical activity places a primary emphasis on heart failure and cardiomyopathies. He currently holds a Canada Research Chair in Heart Failure, Director of the Heart Function Clinic and a Fellow of the Canadian Academy of Health Sciences.</p>
<p>Fred Little Country Lead – Rare Disease Pfizer</p>	<p>Fred Little is a thought leader and a well-respected voice in the rare disease community. He is currently Pfizer Canada's Country lead for Rare Disease and Gene Therapy.</p> <p>Fred has over 25 years of combined international and country leadership experience. Since joining Pfizer Canada in 1999, Fred has been instrumental in bringing innovative medicines successfully in over 50 markets so that patients can receive the care they need as quickly as possible. Prior to leading the rare disease business unit, Fred held leadership roles in sales, marketing, patient access, and government affairs with responsibility for multiple therapeutic areas. Fred began his career in the pharmaceutical industry as an intern at Merck Frosst in 1996, where he worked as a Regional Marketing Analyst and then became part of the Sales team in the Cardiovascular Division.</p> <p>Fred is a committed advocate of developing talent and building high performance teams. Growing up in rural Newfoundland gave Fred the perspective that people with vision, perspective and determination can deliver exceptional outcomes even when resources are limited.</p>



<p>Christopher R. McMaster PhD, FCAHS</p>	<p>Dr. Christopher McMaster, PhD, FCAHS, is the Scientific Director of the Institute of Genetics for the Canadian Institutes of Health Research and Professor of Pharmacology in the Faculty of Medicine at Dalhousie University in Halifax, Canada. Previously, he was the Carnegie and Rockefeller Professor and Head of Pharmacology at Dalhousie University, and was the Assistant Dean for Graduate and Post-doctoral Studies in the Faculty of Medicine at Dalhousie University.</p> <p>His research is broad in interest ranging from basic biochemistry and cell biology, to genomics to determine causal genes for human genetic diseases and their amelioration, to ethical and policy considerations as human genomics is being transitioned toward clinical diagnosis and care. Dr. McMaster has identified several human genes and their functions, including many associated with inherited human disease. His work on therapeutics has resulted in a potential therapy for congenital sideroblastic anemia, and has lead compounds undergoing development for the treatment of the inherited blinding disorder familial exudative vitreoretinopathy and a form of muscular dystrophy.</p>
--	--